溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展

doi:10.11904/j.issn.1002-3070.2021.05.014

Abstract

Abstract: Malignant tumor is considered as the uncontrolled growth and reproduction of cells.In order to avoid being eliminated,tumor cells form a variety of self-protection mechanisms,including resistance to apoptosis and immune escape by affecting the immune system.This makes tumor cells that have a strong ability to proliferate and have a high tendency of invasion and metastasis.Some patients,in the treatment,the effect is not ideal or after treatment,still appears recurrence and metastasis.Therefore,the research and development of new treatment methods are an urgent task.The discovery of oncolytic virus provides a new idea for the treatment of malignant tumors.With the deepening of the research on oncolytic virus,it is found that oncolytic virus can play an anti-tumor role through a variety of mechanisms.In addition to replicating in tumor cells and causing tumor cell lysis,it can also induce tumor cell apoptosis.Besides,oncolytic virus can activate immune cells,initiate anti-tumor immune response and change the immune microenvironment around tumor cells,which can play a long-term anti-tumor effect and inhibit uninfected tumor cells.Oncolytic virus plays a role in both cell apoptosis and anti-tumor immunity,which can effectively resist apoptosis and immune evasion of tumor cells,making a potential anti-tumor therapy.This article aims to introduce the research progress of oncolytic virus through inducing tumor cell apoptosis and activating immune system.

Key words: Malignant tumor, Oncolytic virus, Apoptosis, Immune escape, Immune checkpoint

CLC Number:

R730.5

JIN Shengye, PANG Da. Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity[J]. Journal of Practical Oncology, 2021, 35(5): 462-467.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.05.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I5/462

References

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 SM OB,Mathis JM.Oncolytic virotherapy for breast cancer treatment[J].Curr Gene Ther,2018,18(4):192-205.
3 Mozaffari Nejad AS,Fotouhi F,Mehrbod P,et al.Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C,autophagy and apoptotic pathways[J].Microb Pathog,2020,147:104438.
4 Jiffry J,Thavornwatanayong T,Rao D,et al.Oncolytic reovirus(pelareorep)induces autophagy in KRAS-mutated colorectal cancer[J].Clin Cancer Res,2021,27(3):865-876.
5 Fernald K,Kurokawa M.Evading apoptosis in cancer[J].Trends Cell Biol,2013,23(12):620-633.
6 Coultas L,Strasser A.The role of the Bcl-2 protein family in cancer[J].Semin Cancer Biol,2003,13(2):115-23.
7 Hersey P,Zhang XD.Overcoming resistance of cancer cells to apoptosis[J].J Cell Physiol,2003,196(1):9-18.
8 Elankumaran S,Rockemann D,Samal SK.Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic Caspase-dependent pathways of cell death[J].J Virol,2006,80(15):7522-7534.
9 Fulda S.Targeting apoptosis for anticancer therapy[J].Semin Cancer Biol,2015,31:84-88.
10 Kalantari A,Farashi Bonab S,Keyvanfar H,et al.Evaluation of apoptosis induction by newcastle disease virus laSota strain in human breast carcinoma cells[J].Arch Razi Inst,2020,75(3):367-376.
11 Yang M,Cao X,Yu MC,et al.Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death[J].Hum Gene Ther,2008,19(4):343-353.
12 Koff JL,Ramachandiran S,Bernal-Mizrachi L.A time to kill:targeting apoptosis in cancer[J].Int J Mol Sci,2015,16(2):2942-2955.
13 Whilding LM,Archibald KM,Kulbe H,et al.Vaccinia virus induces programmed necrosis in ovarian cancer cells[J].Mol Ther,2013,21(11):2074-2086.
14 Nichols DB,De Martini W,Cottrell J.Poxviruses utilize multiple strategies to inhibit apoptosis[J].Viruses,2017,9(8):215.
15 Deng L,Yang X,Fan J,et al.IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer[J].Oncol Res,2021,28(6):579-590.
16 Jeong SN,Yoo SY.Novel Oncolytic virus armed with cancer suicide gene and normal vasculogenic gene for improved anti-tumor activity[J].Cancers(Basel),2020,12(5):1070.
17 Zhu W,Zhang H,Shi Y,et al.Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand(TRAIL)inhibits the growth and metastasis of triple-negative breast cancer[J].Cancer Biol Ther,2013,14(11):1016-1023.
18 Hu J,Wang H,Gu J,et al.Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis[J].Acta Biochim Biophys Sin(Shanghai),2018,50(10):1018-1027.
19 Szegezdi E,Logue SE,Gorman AM,et al.Mediators of endoplasmic reticulum stress-induced apoptosis[J].EMBO Rep,2006,7(9):880-885.
20 Faitova J,Krekac D,Hrstka R,et al.Endoplasmic reticulum stress and apoptosis[J].Cell Mol Biol Lett,2006,11(4):488-505.
21 Fabian Z,Csatary CM,Szeberenyi J,et al.p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines[J].J Virol,2007,81(6):2817-2830.
22 Morishima N,Nakanishi K,Takenouchi H,et al.An endoplasmic reticulum stress-specific Caspase cascade in apoptosis.Cytochrome c-independent activation of Caspase-9 by Caspase-12[J].J Biol Chem,2002,277(37):34287-34294.
23 Jia X,Chen Y,Zhao X,et al.Oncolytic vaccinia virus inhibits human hepatocellular carcinoma MHCC97-H cell proliferation via endoplasmic reticulum stress,autophagy and Wnt pathways[J].J Gene Med,2016,18(9):211-219.
24 Tang S,Ning Q,Yang L,et al.Mechanisms of immune escape in the cancer immune cycle[J].Int Immunopharmacol,2020,86:106700.
25 Beatty GL,Gladney WL.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692.
26 Munn DH,Bronte V.Immune suppressive mechanisms in the tumor microenvironment[J].Curr Opin Immunol,2016,39:1-6.
27 Ahmed J,Chard LS,Yuan M,et al.A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery[J].J Immunother Cancer,2020,8(1):e000415.
28 Melchjorsen J.Learning from the messengers:innate sensing of viruses and cytokine regulation of immunity-clues for treatments and vaccines[J].Viruses,2013,5(2):470-527.
29 Stanford MM,Breitbach CJ,Bell JC,et al.Innate immunity,tumor microenvironment and oncolytic virus therapy:friends or foes?[J]Curr Opin Mol Ther,2008,10(1):32-37.
30 Krysko DV,Garg AD,Kaczmarek A,et al.Immunogenic cell death and DAMPs in cancer therapy[J].Nat Rev Cancer,2012,12(12):860-875.
31 Marchini A,Daeffler L,Pozdeev VI,et al.Immune conversion of tumor microenvironment by oncolytic viruses:the protoparvovirus H-1PV case study[J].Front Immunol,2019,10:1848.
32 Hemminki O,Dos Santos JM,Hemminki A.Oncolytic viruses for cancer immunotherapy[J].J Hematol Oncol,2020,13(1):84.
33 Kim Y,Clements DR,Sterea AM,et al.Dendritic cells in oncolytic virus-based anti-cancer therapy[J].Viruses,2015,7(12):6506-6525.
34 Steinman RM,Hemmi H.Dendritic cells:translating innate to adaptive immunity[J].Curr Top Microbiol Immunol,2006,311:17-58.
35 Chaurasiya S,Yang A,Kang S,et al.Oncolytic poxvirus CF33-hNIS-DeltaF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model[J].Oncoimmunology,2020,9(1):1729300.
36 Sivanandam V,LaRocca CJ,Chen NG,et al.Oncolytic viruses and immune checkpoint inhibition:the best of both worlds[J].Mol Ther Oncolytics,2019,13:93-106.
37 Chen L,Han X.Anti-PD-1/PD-L1 therapy of human cancer:past,present,and future[J].J Clin Invest,2015,125(9):3384-3391.
38 Xu F,Jin T,Zhu Y,et al.Immune checkpoint therapy in liver cancer[J].J Exp Clin Cancer Res,2018,37(1):110.
39 Galon J,Bruni D.Approaches to treat immune hot,altered and cold tumours with combination immunotherapies[J].Nat Rev Drug Discov,2019,18(3):197-218.
40 Rajani KR,Vile RG.Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors[J].Viruses,2015,7(11):5889-5901.
41 Dyer A,Baugh R,Chia SL,et al.Turning cold tumours hot:oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference[J].Cancer Gene Ther,2019,26(3-4):59-73.
42 Gujar S,Pol JG,Kroemer G.Heating it up:Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies[J].Oncoimmunology,2018,7(8):e1442169.
43 Mostafa AA,Meyers DE,Thirukkumaran CM,et al.Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer[J].Cancers(Basel),2018,10(6):205.
44 Longo V,Brunetti O,Azzariti A,et al.Strategies to improve cancer immune checkpoint inhibitors efficacy,other than abscopal effect:a systematic review[J].Cancers(Basel),2019,11(4):539.
45 Saha D,Martuza RL,Rabkin SD.Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma[J].Immunotherapy,2018,10(9):779-786.
46 Goradel NH,Mohajel N,Malekshahi ZV,et al.Oncolytic adenovirus:A tool for cancer therapy in combination with other therapeutic approaches[J].J Cell Physiol,2019,234(6):8636-8646.
47 Nakao S,Arai Y,Tasaki M,et al.Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade[J].Sci Transl Med,2020,12(526):7992.
48 Wei D,Xu J,Liu XY,et al.Fighting cancer with viruses:oncolytic virus therapy in china[J].Hum Gene Ther,2018,29(2):151-159.
49 Printz C.FDA approves new treatment of metastatic melanoma[J].Cancer,2016,122(8):1149.
50 Martin NT,Roy DG,Workenhe ST,et al.Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer[J].Sci Rep,2019,9(1):1865.

[1]	FU Yan¹, YAN Lili², WANG Chunyu², FU Fangmin², DONG Hua³. Analysis for the prevalence of malignant tumors in Qionghai city from 2010 to 2016 [J]. Journal of Practical Oncology, 2021, 35(5): 396-401.
[2]	CHEN Xuejian, WANG Wei, ZHOU Jian, LI Ning, ZHANG Haopeng, XU Lishan. Research on the molecular mechanism of regorafenib combined with perifosine in inducing apoptosis of human hepatoma HepG2 cells [J]. Journal of Practical Oncology, 2021, 35(5): 408-413.
[3]	FAN Lin, TIAN Linli, LIU Ming. Research and development of single-cell sequencing technology in head and neck malignant tumors [J]. Journal of Practical Oncology, 2021, 35(5): 472-475.
[4]	DONG Hua, WANG Dingbin, HUA Jing, FAN Kangqiong, MA Nannan, WANG Xingren. Analysis for the incidence and death of malignant tumors in Hainan cancer registry,2016 [J]. Journal of Practical Oncology, 2021, 35(4): 344-350.
[5]	CHEN Lili, LIU Yuqin, DING Gaoheng, SU Haixiang. Epidemic situation about prevention and control of malignant tumor in Gansu province [J]. Journal of Practical Oncology, 2021, 35(3): 254-257.
[6]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[7]	GUO Haonan, QIN Tao. Research progress of MYO10 and malignant tumors [J]. Journal of Practical Oncology, 2021, 35(3): 273-276.
[8]	PAN Hongyan, LI Aiping, LI Qiang. Research progress of the correlation between adipokine omentin-1 and tumor [J]. Journal of Practical Oncology, 2021, 35(3): 282-286.
[9]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[10]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[11]	HU Qihui, DU Yichao, HE Kai, FU Wenguang, XIA Xianming. The role of endoplasmic reticulum stress in liver cancer [J]. Journal of Practical Oncology, 2021, 35(2): 160-164.
[12]	YIN Qi, HU Yanjian, CUI Puze, HU Yanhua. Research progress of Notch signaling pathway in regulating apoptosis of tumor cells [J]. Journal of Practical Oncology, 2021, 35(2): 165-169.
[13]	ZHENG Zhiyuan,QU Guofan. Research progress of long non-coding RNA SNHG3 in malignant tumor [J]. Journal of Practical Oncology, 2021, 35(1): 50-54.
[14]	YANG Siqi,SONG Qibin,LI Qingqing,YAO Yi. Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 73-77.
[15]	WEN Hongmei, CHEN Yang, SHI Qingping, REN Siying, GAO Jiao, QIN Mingfang. Analysis of cancer incidence and mortality in Yunnan cancer registry,2016 [J]. Journal of Practical Oncology, 2020, 34(6): 485-490.

Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments